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Abstract
Translesion DNA synthesis (TLS) functions as a tolerance mechanism for DNA damage at a
potentially mutagenic cost. Three TLS polymerases (Pols) function to bypass DNA damage in
Saccharomyces cerevisiae: Rev1, Pol ζ, a heterodimer of the Rev3 and Rev7 proteins, and Pol η
(Rad30). Our lab has shown that S. cerevisiae Rev1 protein levels are under striking cell cycle
regulation, being ~50-fold higher during G2/M than during G1 and much of S phase (Waters and
Walker, 2006). REV1 transcript levels only vary ~3-fold in a similar cell cycle pattern, suggesting
a posttranscriptional mechanism controls protein levels. Here, we show that the S. cerevisiae Rev1
protein is unstable during both the G1 and G2/M phases of the cell cycle, however the protein’s
half-life is shorter in G1 arrested cells than in G2/M arrested cells, indicating that the rate of
proteolysis strongly contributes to Rev1’s cell cycle regulation. In the presence of the proteasome
inhibitor, MG132, the steady-state levels and half-life of Rev1 increase during G1 and G2/M.
Through the use of a viable proteasome mutant, we confirm that the levels of Rev1 protein are
dependent on proteasome-mediated degradation. The accumulation of higher migrating forms of
Rev1 under certain conditions shows that the degradation of Rev1 is possibly directed through the
addition of a polyubiquitination signal or another modification. These results support a model that
proteasomal degradation acts as a regulatory system of mutagenic TLS mediated by Rev1.
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1. Introduction
Cells constantly face the challenge of maintaining genomic integrity as a result of DNA
damage arising from endogenous and exogenous sources. To prevent the negative
consequences of DNA damage, the cell is equipped with DNA repair and tolerance
mechanisms. DNA repair restores the original state of the DNA. DNA damage tolerance,
however, allows DNA lesions to remain in the genome even during replication.
When the cell employs translesion DNA synthesis (TLS) to tolerate DNA damage,
specialized DNA polymerases with members from all domains of life [1] catalyze
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replication opposite lesions that normally prevent the replicative DNA polymerases’
activity. Most TLS polymerases belong to the Y-family of DNA polymerases, which are
better able to accommodate bulky DNA lesions because the active sites are less sterically
constrained than those of the high-fidelity, replicative polymerases [2]. Given this structural
property of TLS polymerases and their lack of any proofreading activity, TLS polymerases
can exhibit high error rates. TLS across from lesions can be relatively error-free or quite
error-prone depending on the lesion and polymerase involved [3–5]. Following bypass, the
DNA repair pathways can later remove the DNA lesion, which remains in the DNA.
There are three known TLS polymerases in S. cerevisiae: Rev1 and Pol η (Rad30) of the Y-
family and the B-family member, Pol ζ, a heterodimer of Rev3 and Rev7. All three are
highly conserved among eukaryotes. The REV1, REV3, and REV7 genes were discovered in
screens for reversionless mutants in yeast (a phenotype indicating loss of a mutagenic
activity) [6,7]. The rev1Δ mutant phenotypes include an increased sensitivity to certain
DNA damaging agents and a decreased damage-induced mutation frequency, indicating
Rev1’s instrumental role in DNA damage resistance and mutagenesis [8].
Rev1’s DNA polymerase activity exhibits unique properties that include specificity for a
template G and a preference for inserting dCMPs as a consequence of pairing the incoming
dNTP with one of its own residues instead of with a template base [9–11]. Despite this clear
and evolutionarily conserved catalytic activity (Wiltrout and Walker, submitted), the non-
catalytic functions of Rev1 appear to be more critical for DNA damage tolerance and
mutagenesis in vivo based on known mutant phenotypes. In S. cerevisiae, the rev1-1
(G193R) mutant of the BRCT domain leads to almost null phenotypes in vivo, but the
mutant protein retains about 60% of the catalytic activity in vitro [12]. Additionally, the
ubiquitin binding motif (UBM2) [13–15] and the conserved region of Rev1’s C-terminus
that interacts with other TLS polymerases [16–20] are critical for cellular survival and
mutagenesis after DNA damage [reviewed in [21]]. Therefore, beyond its DNA polymerase
function, Rev1 serves to regulate the other TLS polymerases through protein-protein
interactions or direct interaction with the DNA.
The mutagenic nature of Rev1 indicates that the activity must be tightly regulated. The
conservation of Rev1 in higher eukaryotes suggests that the evolutionary benefits outweigh
the risks of its potentially mutagenic activity, although it is possible that all of Rev1’s in vivo
functions are not known.
Not surprisingly, disrupting the normal protein levels of TLS polymerases has negative
consequences. In S. cerevisiae, ectopic overexpression of Pol ζ’s Rev3 and Rev7 proteins
leads to a greater sensitivity to UV radiation and an increase in UV-induced mutation
frequency [22]. In one study in mammalian cells, a 2 to 4.5-fold overexpression of the TLS
DNA Pol κ interferes with replication fork progression in CHO cell lines [23]. In another
report one study, overexpression of human REV1 in ovarian carcinoma cells demonstrates
the potential danger of misregulated Rev1 levels [24]. Therefore, understanding how the
regulation of REV1 properly balances survival and mutagenesis in the cell is crucial.
Currently, limited data exists regarding the regulation of REV1 gene expression. Unlike
some other genes encoding DNA repair proteins, S. cerevisiae REV1 transcription is not
inducible by DNA damage or heat shock [25]. REV1 transcript levels are, however,
upregulated during sporulation in S. cerevisiae [26–28]. At the protein level, previous work
from our lab has shown that Rev1 is under striking cell cycle control with protein levels
peaking during G2/M rather than S phase when the bulk of replication occurs [29]. Despite
the approximately 50-fold change at the protein level, REV1 transcript levels only increase
3-fold during G2/M relative to G1. Interestingly, Rev1 is phosphorylated in a similar cell
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cycle-dependent manner, demonstrating another potential method of regulation [30]. The
molecular means controlling the unexpected cell cycle regulation of Rev1, however, are not
yet fully understood.
More recent studies support the hypothesis that cell cycle regulation of Rev1 is functionally
important. For example, the action of Rev1 and Pol ζ is key for bypass of ultraviolet-induced
DNA damage during and after S phase of the cell cycle and can occur separately from bulk
genomic replication [31]. In another study, the use of G2-specific promoters to express Rev3
and Rad30 complemented the deletion of the TLS polymerases with respect to survival and
mutagenesis phenotypes in response to specific types of DNA damage [32]; a G2-specific
promoter was not used to express Rev1 in this study.
Several genetic studies indicate that TLS may be subject to regulation by the proteasome.
These studies took advantage of the ump1Δ strain, which is a viable mutant of a gene
encoding a maturation factor for the 20S catalytic core of the 26S proteasome [33]. The
spontaneous and UV-induced mutator phenotype of the ump1Δ strain is dependent on the
TLS polymerase gene, REV3, which is generally placed in the same genetic pathway as
REV1 [34,35]. The ump1Δ strain is hypermutable, whereas rev3Δ and ump1Δ rev3Δ strains
are hypomutable, suggesting that Ump1 may act as a negative regulator of Rev3 activity,
possibly through Rev1’s interaction with Pol ζ. The authors of this study, however, did not
examine REV1’s genetic interactions with UMP1. In an ump1 strain, short-lived proteins are
stabilized and ubiquitin-protein conjugates accumulate [33]. Therefore, we hypothesized the
involvement of proteasomal degradation in TLS regulation as a means for control of this
potentially mutagenic process.
Selective protein turnover through ubiquitination and subsequent proteasomal degradation
represents an essential regulatory mechanism in eukaryotic cells. The irreversibility of
protein degradation ensures both spatial and temporal control and eliminates improper
reactivation of the protein. The attachment of monoubiquitin or polyubiquitin chains to
specific proteins is critical for a variety of cellular processes from DNA repair and
replication to gene silencing, in addition to protein degradation [36,37].
Here, we studied the role that proteasomal degradation has in regulating the mutagenic TLS
polymerase Rev1, the levels of which are cell cycle regulated. We show that Rev1 is a
moderately short-lived protein throughout the cell cycle but is degraded more rapidly during
G1 than during G2/M. Our data indicate that Rev1 undergoes proteasome-mediated
degradation during both G1 and G2/M arrests that is potentially targeted through a
polyubiquitin modification. Overall, these results indicate that proteasomal degradation
serves as an efficient and irreversible mechanism of regulating the potentially mutagenic
effects of Rev1’s action.
2. Material and methods
2.1. Yeast strains
A strain list for this study is described in Table 1. All strains are derivatives of the
W1588-4C (MATa leu2-3,112 ade2-1 can1-100 his3-11,15 ura3-1 trp1-1 RAD5) [38] parent
strain. The Rev1 protein was tagged at its native locus with a C-terminal TEV-ProA-His7
epitope tag (marked with HIS3) using pYM10 [39], similar to that previously described
[17,29]. UMP1 and ERG6 (also called ISE1) were each separately deleted via a one-step
replacement, amplifying the ump1::kanMX4 or erg6::kanMX4 cassette from the deletion
library and transforming the product into the appropriate strain background [40]. The BAR1
gene was disrupted by a one-step gene replacement using digested pZV77 to aid in arresting
cells with α factor (gift from S. Bell). The multicopy vector, pMRT7 (pCK322), contains the
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PCUP1-myc-UBI expression cassette and the URA3 marker [41] (gift from C. Kaiser). All
cassettes and plasmids were introduced through a standard lithium acetate protocol [42].
Oligonucleotide sequences that were used in strain construction are available up request.
2.2. Cell cycle arrest
Cells were grown in YEPD media at 30°C with the exception of ump1Δ strains that were
grown at 25°C. When the culture reached an OD of 0.5, the cells were split into two cultures
for arrest, one G1 arrested with α factor (50 ng/ml) and the other G2/M arrested with
nocodazole (15μg/ml). Cells were treated for 3 to 4 hours prior to starting the assays.
2.3. Immunoblot
Protein extracts were made using a trichloroacetic acid (TCA) procedure similar to that
published [39]. TCA precipitations were run on 7.5% SDS-PAGE gels (Lonza), and the
immunoprecipitation samples were run on NuPAGE 3–8% tris-acetate gels (Invitrogen)
before being transferred to polyvinylidene difluoride membranes (PVDF, Immobilon-P;
Millipore). PVDF membranes were probed with rabbit peroxidase-anti-peroxidase soluble
complex (PAP, Sigma) for ProA-tagged proteins and anti-3-phosphoglycerate kinase (yeast),
mouse IgG, monoclonal antibody (anti-PGK, Molecular Probes) with mouse secondary for
the Pgk1 control.
2.4. Flow cytometry
Cells were prepped as in [43] and analyzed on a Becton Dickinson FACSCalibur flow
cytometer.
2.5. Cycloheximide chase assay
G1 or G2/M arrested cells were treated with cycloheximide (Sigma) (50 μg/ml) after the full
3 to 4 hours for arrest. For logarithmic growing cells, cultures were grown to an equivalent
O.D. of 0.7, and then cycloheximide was added at 50 μg/ml to start the time course. At
specific time points, cells were collected for flow cytometry (0.5 ml) or TCA precipitations
(1.5 ml). Cells for TCA precipitations were immediately spun down, frozen in liquid
nitrogen, and stored at −20°C.
2.6. Proteasome inhibitor assay
Cultures were treated with MG132 (Z-Leu-Leu-Leu-al, 50 μM, Sigma) for G1 and G2/M
arrested cells. All experiments involving MG132 were completed in an erg6Δ (ise1 ) strain
background to allow for MG132 permeability [44]. The cells were collected as described in
Section 2.5.
2.7. Immunoprecipitation
Lysis and immunoprecipitations were carried out as described [16] with the following
modifications. The immunoprecipitated strains were subcultured into 500 ml of SC media
lacking uracil (for selection of pMRT7) or histidine (for the strain lacking the plasmid) and
grown to an OD of 0.7 at 25°C. Copper sulfate (0.5 μM) was added to induce the expression
of Myc-tagged ubiquitin. Cells were harvested in 50 ml tubes, washed in cold water,
transferred to and pelleted in 2 ml screw cap tubes, and stored in lysis buffer at −80°C until
the remaining steps of the lysis and immunoprecipitation protocol were completed.
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3. Results
3.1. S. cerevisiae Rev1 is unstable during the G1 and G2/M phases of the cell cycle
Given Rev1’s profound cell cycle regulation, we wanted to know to what extent protein
degradation contributes to the significant drop in Rev1 levels during the G1 stage of the cell
cycle. Proteolysis influences the cell cycle regulation of many proteins in S. cerevisiae [45].
To monitor Rev1 protein stability, we inhibited translation by adding cycloheximide to
arrested cells, collected samples at subsequent time points, and visualized ProA-tagged Rev1
by immunoblot. REV1 was expressed under its native promoter at the endogenous locus, and
the protein produced had a tag at its C-terminus that does not affect Rev1’s contribution to
survival and mutagenesis after UV damage [29]. Cells were arrested during the G1 stage of
the cell cycle with α factor and during the G2/M stages with nocodazole. Interestingly, Rev1
is unstable during both G1 when protein levels are the lowest and during G2/M when protein
levels are highest (Fig. 1A and B). The flow cytometry data indicates that the cells remain in
the arrested state even after the addition of cycloheximide (1N DNA content for G1 arrested
cells, 2N DNA content for G2/M arrested cells) (Fig. 1C and D). Our measurements indicate
that the half-life of Rev1 during a G1 arrest is 18 minutes and 32 minutes during a G2/M
arrest (Fig. 1E and F) as determined by densitometry measurements and half-life
calculations performed similarly to that described by Belle et al. [46]. Since Rev1 protein is
degraded faster during G1 arrest when protein levels are the lowest than during G2/M arrest
when protein levels are the highest, these results suggest that protein degradation acts as a
necessary component of Rev1’s striking cell cycle regulation. The slower degradation
during G2/M, when Rev1 levels are highest, may be a means to limit Rev1 levels throughout
the cell cycle.
3.2. Inhibition of the proteasome causes an increase in Rev1 protein levels
After learning that Rev1 protein is unstable throughout the cell cycle with faster degradation
in G1 than in G2/M, we asked whether this property was dependent on proteasomal
degradation. We used the proteasome inhibitor, MG132, and assessed Rev1 protein levels
following treatment. All experiments involving MG132 were performed in an erg6
background to allow the drug to enter the cells. The steady-state level of Rev1 protein
increased in the presence of the proteasome inhibitor for both G1 and G2/M arrested cells
indicating that the proteasome function is associated with Rev1’s degradation (Fig. 2A and
B). Flow cytometry analysis confirmed that the erg6Δ cells arrest normally in the absence or
presence of proteasome inhibitor (data not shown, also see Fig. 2E and F).
3.3. The proteasome is responsible for Rev1’s relatively short half-life
To monitor the effect that the disruption of proteasome function has on the half-life of Rev1
protein, G1 and G2/M arrested cells were pre-incubated with MG132 for 30 minutes. The
time course began with the addition of cycloheximide. The half-life of Rev1 during G1 or
G2/M arrest is longer in the presence of proteasome inhibitor than when translation is
inhibited in its absence (Fig. 2C and D). The flow cytometry data does not show any
abnormalities for the arrests (Fig. 2E and F). As seen in another report [47], MG132 does
not completely prevent degradation of Rev1 in this cycloheximide-chase assay.
3.4. Rev1 steady-state levels increase when proteasome function is defective
To further support our proteasome inhibitor results with a genetic approach, we utilized one
of the viable mutants associated with the assembly of the proteasome (ump1 ), which lacks
the gene encoding a maturation factor for the 20 S proteasome. In cells that have been
arrested by α factor or nocodazole, the steady-state levels of Rev1 are significantly greater in
the ump1Δ cells than in wild type cells during G1 and are moderately increased during G2/
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M (Fig. 3A and B at time points 0) similar to the effect observed after the addition of the
proteasome inhibitor drug. These experiments were carried out at 25°C instead of 30°C to
avoid problems with the temperature sensitivity of an ump1Δ strain. Rev1 levels are much
greater in the ump1Δ background during the G1 arrest. In fact, Rev1 is not even visible in
the blot of the wild type strain in the exposure selected to illustrate Rev1 levels in the
ump1Δ mutant (Fig. 3A). A similar large increase in Rev1 levels was not observed after the
addition of nocodazole, and the half-life of Rev1 in the ump1Δ strain during nocodazole
arrest does not seem to significantly differ from the estimated half-life in wild type from Fig.
1F (Fig. 3B). However, this discrepancy appears to arise from an effect of the deletion of
UMP1 on the cellular response to nocodazole. The flow cytometry reveals that the ump1Δ
cells arrest normally with α factor but fail to properly arrest in nocodazole (Fig. 3C and D).
This is most likely due to the pleiotropic nature of phenotypes as a result of deleting UMP1.
Since more cells accumulate with 1N DNA content (when Rev1 levels are the lowest) in
ump1Δ cells treated with nocodazole than with a wild type strain, the Rev1 protein levels
shown in Fig. 3B are an underestimate of the levels actually present during G2/M. These
results indicate that the proteasome is involved in the degradation of Rev1 and are consistent
with the data obtained using MG132. The differences seen between the proteasome inhibitor
and proteasome assembly mutant experiments can be attributed to the pleotropic effects of
deleting UMP1 and only partial loss of proteasome function in both cases.
3.5. Higher migrating forms of Rev1 indicate targeting of the protein to the proteasome
After observing that the disruption of proteasome function affected Rev1 protein levels, we
assessed whether Rev1 is modified to be targeted to the proteasome. In general, the
attachment of a polyubiquitin chain of at least four Lys48-linked ubiquitins will target
proteins for degradation by the 26S proteasome [48]. To detect higher migrating forms of
Rev1 and subsequently test if these forms represent polyubiquitinated Rev1, we
immunoprecipitated ProA-tagged Rev1 in an ump1 strain background (Fig. 3E, lane 2). This
strain also included myc-tagged ubiquitin under a copper-inducible promoter. We compared
this immunoprecipitation to one of ProA-tagged Rev1 in an UMP1 strain lacking myc-
tagged ubiquitin (Fig. 3E, lane 1) and to another immunoprecipitation of non-tagged Rev1 in
an ump1 strain with myc-tagged ubiquitin (Fig. 3E, lane 3). When probing for ProA-tagged
Rev1, a significant smear appears above the Rev1 band for the immunoprecipitation done in
the presence of myc-tagged ubiquitin in an ump1 background (Fig. 3E, lane 2). No Rev1 is
detected when the protein lacks the ProA tag (Fig. 3E, lane 3).
The blot for myc-tagged ubiquitin with anti-myc after immunoprecipitation showed no
bands and for anti-ubiquitin did not show any distinct bands or smears corresponding to
Rev1’s migration or higher that were specific to the ProA-tagged Rev1
immunoprecipitations (data not shown). In both cases, this could be due to Rev1 protein
levels still being very low even after the immunoprecipitation, given that they are only
detectable with by immunoblot of the ProA tag and not silver stain. The anti-myc or anti-
ubiquitin may not be sensitive enough to detect the small fraction of Rev1 that is modified.
Also, the anti-ubiquitin blot is not ideal, since the immunoblot had a very high background
despite the fact that we had immunoprecipitated the protein of interest.
The higher migrating smear in lane 2 (Fig. 3E) implies that a modified form of Rev1 exists
and is more easily detected in the ump1Δ strain background. Since the deletion of ump1 is
known to cause an accumulation of ubiquitin-conjugated proteins [33], it seems likely that
the smear in lane 2 (Fig. 3E) represents polyubiquitinated Rev1. However, the very low
levels of the Rev1 present in cells made these experiments technically challenging and thus
we cannot conclusively rule out the possibility that the Rev1 modification associated with its
degradation results from another protein modification.
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4. Discussion
Since Rev1 protein levels fluctuate ~50-fold as cells progress through the cell cycle and
transcript levels only undergo a ~3-fold change [29], we hypothesized that proteolysis
contributes to the cell cycle regulation of Rev1. Indeed, we find that Rev1 is degraded
during both G1 and G2/M in a manner that is dependent on the proteasome function, with
the half-life during G1 being shorter than during G2/M. Faster degradation of Rev1 by the
proteosome during G1 than during G2/M seems to be a major mechanism responsible for
Rev1’s striking cell cycle regulation. Aside from the transcriptional and proteasomal
mechanisms of regulation, it is possible that some other posttranscriptional mechanism
could also contribute to the significant increase of Rev1 protein levels during G2/M.
Degradation by the proteasome serves as an excellent mechanism to ensure the proper
timing and positioning of a protein for action. Proteolysis eliminates the protein in an
effective and irreversible way to prevent action and can destroy aberrant proteins. For
potentially mutagenic TLS polymerases, ensuring that these polymerases do not interfere
with the replicative DNA polymerases and only function when needed is critical to avoid
widespread mutagenesis. These results demonstrate that S. cerevisiae uses proteasomal
degradation to keep Rev1 protein levels low in general or low at specific times in the cell
cycle. Similarly, TLS proteins are regulated by degradation in E. coli. For example, UmuC,
the catalytic subunit of Pol V, undergoes proteolysis by the Lon protease [49].
In higher eukaryotes, more data is emerging that other DNA polymerases involved in base
excision repair and capable of TLS, Pols λ and β, are targeted for proteasome-mediated
degradation [50,51]. Interestingly, phosphorylation of Pol λ stabilizes the protein during late
S and the G2/M stages of the cell cycle. These are the same cell cycle stages that Rev1
protein levels are the highest and phosphorylated in S. cerevisiae [30]. Future work will be
required to know if Rev1 degradation is modulated by phosphorylation or if Rev1 is targeted
for degradation through another protein modification.
A few examples of ubiquitin-independent proteasomal degradation exist such as Spe1
degradation mediated by the interaction with Oaz1 in S. cerevisiae [52]. If not
polyubiquitination, the higher migrating form of Rev1 could represent another protein
interacting with Rev1 or phosphorylation of specific residue(s) or the addition of alternative
protein modifications. If the higher migrating form of Rev1 is due to polyubiquitination,
then the attachment of polyubiquitin on Rev1 will involve an E2 and E3 ubiquitin ligase.
The timing of the anaphase-promoting complex/cyclosome (APC/C) activity coincides with
the lowest levels of Rev1 occurring during G1. The APC/C, a multisubunit ubiquitin-protein
ligase, controls cell cycle progression by targeting key proteins for 26S proteasome
degradation during late mitosis and G1 [45]. As shown here though, Rev1 is degraded
throughout the cell cycle and therefore may not be a substrate for classical ubiquitin ligases
associated with cell cycle regulation.
Our initial discovery that Rev1 protein levels peak during the G2/M phase of the cell cycle
had seemed inconsistent with this translesion DNA polymerase functioning mainly during S
phase. Furthermore, Lopes et al. [53] observed that in UV-irradiated S. cerevisiae, small
ssDNA gaps accumulate along replicated duplexes that likely result from the repriming of
DNA synthesis downstream of UV lesions on both leading and lagging strands. Their
observation that TLS can help to counteract the accumulation of these gaps without affecting
fork progression led them to suggest that the bulk of TLS takes behind replication forks and
thus contributes postreplicatively to restore the integrity of replicated duplexes [53]. More
recent studies have lent further support to the concept that TLS polymerases act post bulk
genomic replication and during G2/M (in addition to during S phase) for full DNA damage
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tolerance [31,32,54-56]. It seems likely that the control of Rev1 levels through cycle cycle-
dependent proteosomal degradation is an important way of limiting the action of Rev1/3/7-
dependent mutagenic TLS more to G2/M. Such a strategy can reduce the amount of
mutagenesis occurring after DNA damage by delaying some portion of mutagenic TLS until
after high fidelity repair and more accurate damage tolerance mechanisms have had a chance
to act [29]. This would be especially important for cells undergoing replication and
experiencing large amounts of DNA damage. Under these circumstances, DNA repair might
not have enough time to completely remove all of the lesions before replication takes place,
thereby leading to postreplicational gaps opposite lesions in G2/M.
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Fig. 1.
Rev1 protein experiences turnover during the G1 and G2/M phases of the cell cycle. (A)
Rev1 levels decrease during G1 arrest after cycloheximide treatment. The cells from the
Rev1-ProA strain were arrested with α factor at 30°C, and then split into a cycloheximide
treated culture and a non-treated culture before time points were collected each hour.
Immunoblots are probed with PAP for the ProA-tagged Rev1 and with anti-Pgk1 for the
Pgk1 loading control. (B) Rev1 levels decrease during G2/M arrest after cycloheximide
treatment. The assay was performed as in (A), except that the arrest was done with
nocodazole. (C) Rev1-ProA cells stay arrested after cycloheximide treatment with 1N DNA
content. Flow cytometry data is shown for α factor-arrested cells with and without
cycloheximide. (D) Rev1-ProA cells remain in G2/M arrest after the addition of
cycloheximide. Flow cytometry data is given for nocodazole-arrested cells in the presence
and absence of cycloheximide. (E) The half-life of Rev1 in G1 arrested cells is less than in
G2/M arrested cells. The half-life was estimated to be 18 minutes. The assay for the
immunoblot was carried out as in (A), except that time points were taken at smaller
intervals. (F) The half-life of Rev1 in G2/M arrested cells is greater than in G1 arrested
cells. The half-life is estimated to be 32 minutes. The assay was completed as in (E), except
that cells were arrested with nocodazole.
Wiltrout and Walker Page 12
DNA Repair (Amst). Author manuscript; available in PMC 2012 February 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Normal proteasome function regulates Rev1 protein levels. (A) Rev1 protein levels
significantly increase in the presence of the proteasome inhibitor, MG132, in G1 arrested
cells. Cells were arrested with α factor at 30°C, and then divided into a MG132 treated and
non-treated cultures before time points were taken. The strain background is erg6Δ. The
immunoblot was probed with PAP for ProA-tagged Rev1 and anti-Pgk1 for the Pgk1
loading control. (B) Rev1 protein levels are also greater after MG132 treatment in G2/M
arrested cells. The assay was carried out as in (A), apart from the arrest being done with
nocodazole. (C) Rev1 protein levels are stabilized when the proteasome is inhibited during
G1. After a pre-incubation of α factor-arrested cells with MG132 at 30°C, cycloheximide
was added to start the time course. The strain background is erg6Δ. The immunoblot shows
Pro-tagged Rev1 and the loading control, Pgk1. (D) The half-life of Rev1 during G2/M is
also lengthened in the presence of MG132. The assay was performed as in (C), but cells
were arrested with nocodazole. (E) Cells maintain 1N DNA content after MG132 and
cycloheximide treatment. Flow cytometry data is shown for select time points in the
presence of cycloheximide alone or cycloheximide and MG132. (F) MG132 does not affect
the nocodazole arrest. Flow cytometry data is depicted as in (E), apart from the cells being
in a G2/M arrest.
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Fig. 3.
The steady-state levels of Rev1 are greater in a proteasome-defective strain background, and
a higher migrating form of Rev1 accumulates. (A) Rev1 protein levels increase in the
ump1Δ background during G1 arrest. Cells were arrested with α factor at 25°C, and then
treated with cycloheximide to start the time course using the Rev1-ProA or Rev1-ProA
ump1Δ strains. The immunoblot shows ProA-tagged Rev1 and Pgk1 as a loading control.
(B) Rev1 protein levels are greater in the ump1Δ background during G2/M arrest. The assay
was completed as in (A), except that the cells were arrested with nocodazole. (C) The
ump1Δ strain background does not change the ability of cells to arrest with 1N DNA
content. Flow cytometry is shown for the Rev1-ProA or Rev1-ProA ump1Δ strains during α
factor arrest. (D) The ump1Δ cells accumulate more with 1N DNA content during
nocodazole arrest than the wild type background. Flow cytometry shows the DNA content
for G2/M arrested cells of the Rev1-ProA or Rev1-ProA ump1Δ strains. (E) A higher
migrating form of Rev1 exists when UMP1 is deleted and myc-tagged ubiquitin is
overexpressed. Strains are Rev1-ProA (lane 1), Rev1-ProA ump1Δ + pMRT7 (lane 2), and
W1588-4C ump1Δ + pMRT7 (lane 3). The immunoblot for the Rev1-ProA
immunoprecipitation samples were probed with PAP for ProA-tagged Rev1.
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Table 1
Yeast strains used in this study.
Strain Relevant Genotype Source
YLW70 W1588-4C bar1Δ::LEU2 [16]
Rev1-ProA W1588-4C bar1Δ::LEU2 REV1-TEV-ProA-7HIS [29]
Rev1-ProA ump1Δ same as Rev1-ProA but ump1Δ::kanMX4 This study
Rev1-ProA erg6Δ same as Rev1-ProA but erg6Δ::kanMX4 This study
W1588-4C ump1Δ + pMRT7 W1588-4C bar1Δ::LEU2 ump1Δ::kanMX4 p PCUP1- myc-UBI This study
Rev1-ProA ump1Δ + pMRT7 Same as Rev1-ProA ump1Δ with pPCUP1-myc-UBI This study
All strains are derivatives of W1588-4C (MATa leu2-3,112 ade2-1 can1-100 his3-11,15 ura3-1 trp1-1 RAD5) [38].
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